Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — November 2023

Genmab — November 2023

Planlagt Fastgjort Låst Flyttet Genmab
1.5k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • S Offline
    S Offline
    Stroka
    wrote on sidst redigeret af
    #6

    God morgen 🙂

    1 Reply Last reply
    0
    • B Offline
      B Offline
      bibob
      wrote on sidst redigeret af
      #7

      God morgen. 🙂

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #8

        Tepezza was discussed quite a bit on the AMGN earnings call, would recommend reading eg via seekingalpha

        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #9

          https://www.fool.com/earnings/call-transcripts/2023/10/31/pfizer-pfe-q3-2023-earnings-call-transcript/ Pfizer (PFE) Q3 2023 Earnings Call Transcript 'They recently started two Phase 3 studies, one with tisotumab vedotin with -- in combination with pembrolizumab in advanced metastatic HER2-positive or HER2 bladder cancer. This is a program that we're very excited about. Already, tisotumab received previously breakthrough therapy designation in the U.S.'

          1 Reply Last reply
          0
          • E Offline
            E Offline
            E_L
            wrote on sidst redigeret af
            #10

            Obviously, we remain very confident that we will close Seagen toward the end of this year, beginning next year. I should point it out there's a significant interest now in ADCs because of the potential that they could replace most of the chemotherapeutics in the future for most cancer types. Seagen, obviously, has a significant track record with
            current approved ADCs from their laboratories.

            1 Reply Last reply
            0
            • P Offline
              P Offline
              peter12
              wrote on sidst redigeret af
              #11

              Bladder mener jeg var der TV virkede bedst ? Men Seagen har deres egen ADC også i Bladder ?

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #12

                i don't think there is currently a tisotumab trial on bladder cancer. We know tissue factor is expressed on bladder tumors and we know from (the completed) InnovaTV 201 that TV had a high respons in bladder cancer, but i don't know of any plans of Ph3 trials for bladder.

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #13

                  Maybe he made a mistake indeed and mixed it up with Enfortumab Vedotin which had very good bladder data at ESMO

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #14

                    Jyske still positive https://www.jyskebank.dk/wps/wcm/connect/jfo/2fa1f4e9-90e5-41c0-8af6-d8fd177bdf65/Danske+Aktier+Oktober+2023+færdig.pdf?MOD=AJPERES&CACHEID=ROOTWORKSPACE.Z18_P20418S0N05640Q0MBPDFT1PE7-2fa1f4e9-90e5-41c0-8af6-d8fd177bdf65-oK5iULz

                    1 Reply Last reply
                    0
                    • troldmandenT Offline
                      troldmandenT Offline
                      troldmanden
                      wrote on sidst redigeret af
                      #15

                      Ja. Og jyske har PE 30 på 2023 forventning. De har PE 38 for novo 2023 forventninger. Novo kommer de dog til at justere op

                      1 Reply Last reply
                      0
                      • K Offline
                        K Offline
                        Klarussen
                        wrote on sidst redigeret af
                        #16

                        @thanks for the update E L on Jyske Banks recommendations 🙂

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #17

                          TIVDAK Q3 '23
                          $23mn , $64mn YTD 'TIVDAK growth reflects continued uptake in its current indication.' https://www.businesswire.com/news/home/20231101283813/en/Seagen-Third-Quarter-2023-Financial-Results-Reflect-Strong-Product-Sales-Growth-and-Significant-Portfolio-and-Pipeline-Progress

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #18

                            so we should end up ~$90mn for the year, not bad for the current
                            indication.

                            1 Reply Last reply
                            0
                            • L Offline
                              L Offline
                              lahn1
                              wrote on sidst redigeret af
                              #19

                              Hvad er Gmabs royalty på TV?

                              1 Reply Last reply
                              0
                              • B Offline
                                B Offline
                                bikube
                                wrote on sidst redigeret af
                                #20

                                Er det fordi renten i USA vender ned, at kursen nu endelig vender op?

                                1 Reply Last reply
                                0
                                • StockBullS Offline
                                  StockBullS Offline
                                  StockBull
                                  wrote on sidst redigeret af
                                  #21

                                  50%

                                  1 Reply Last reply
                                  0
                                  • StockBullS Offline
                                    StockBullS Offline
                                    StockBull
                                    wrote on sidst redigeret af
                                    #22

                                    Genmab omsatte for 332 mil usd i 2022

                                    1 Reply Last reply
                                    0
                                    • StockBullS Offline
                                      StockBullS Offline
                                      StockBull
                                      wrote on sidst redigeret af
                                      #23

                                      332 mil kr

                                      1 Reply Last reply
                                      0
                                      • troldmandenT Offline
                                        troldmandenT Offline
                                        troldmanden
                                        wrote on sidst redigeret af
                                        #24

                                        Genmab får ikke royalties af TV. De bogføre 50% af oms, men står så tilsvarende for udgifter til supply chain, salg og marketing og fortsættende kliniske studier. Så der er nok lidt vej endnu inden break even

                                        1 Reply Last reply
                                        0
                                        • StockBullS Offline
                                          StockBullS Offline
                                          StockBull
                                          wrote on sidst redigeret af
                                          #25

                                          Ja hvis der kun er solgt for 64m usd for første 9 mdr når de nok ikke 332 mil kr for 2023 så tilbagegng i.f.t 2022

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper